- Home
- STRO vs AVIR Comparison
STRO vs AVIR Comparison
Compare STRO & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STRO | AVIR |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.0M | 236.7M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | STRO | AVIR |
|---|---|---|
| Price | $9.90 | $3.14 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 8 | 1 |
| Target Price | ★ $18.29 | $6.00 |
| AVG Volume (30 Days) | 121.9K | ★ 364.5K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $105,646,000.00 | N/A |
| Revenue This Year | $63.08 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.23 | $2.46 |
| 52 Week High | $21.50 | $4.02 |
Technical Indicators
Market Signals| Indicator | STRO | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 80.29 | 52.31 |
| Support Level | $8.49 | $3.11 |
| Resistance Level | $10.10 | $3.27 |
| Average True Range (ATR) | 0.98 | 0.09 |
| MACD | 0.12 | 0.01 |
| Stochastic Oscillator | 100.00 | 65.34 |
Price Performance
Historical ComparisonAbout STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).